BioNTech SE Sponsored ADR (NASDAQ:BNTX) Stock Has Average Price Target of $126.00 According to Brokerages

Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) have received an average rating of “Moderate Buy” from the nineteen analysts that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $126.00.

Several analysts have issued reports on BNTX shares. UBS Group reaffirmed a “buy” rating on shares of BioNTech in a research report on Wednesday, September 16th. Wall Street Zen lowered shares of BioNTech from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Canaccord Genuity Group dropped their target price on shares of BioNTech from $142.00 to $136.00 and set a “buy” rating on the stock in a report on Monday, August 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioNTech in a research note on Friday. Finally, Citigroup reduced their price target on BioNTech from $130.00 to $125.00 and set a “buy” rating for the company in a report on Wednesday, August 5th.

Insider Activity at BioNTech

In related news, CEO Ugur Sahin sold 17,000 shares of the company’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $97.46, for a total value of $1,656,820.00. Following the transaction, the chief executive officer owned 197,209 shares in the company, valued at approximately $19,219,989.14. This represents a 7.94% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 627,000 shares of company stock worth $61,967,005. Insiders own 19.20% of the company’s stock.

Institutional Investors Weigh In On BioNTech

A number of institutional investors have recently made changes to their positions in BNTX. Integrated Wealth Concepts LLC bought a new stake in BioNTech in the 2nd quarter valued at $39,000. Caitong International Asset Management Co. Ltd increased its position in BioNTech by 1,012.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 556 shares of the company’s stock worth $53,000 after buying an additional 506 shares during the period. Vestcor Inc acquired a new stake in shares of BioNTech during the fourth quarter worth $153,000. Rockefeller Capital Management L.P. lifted its holdings in shares of BioNTech by 328.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,856 shares of the company’s stock worth $177,000 after buying an additional 1,423 shares in the last quarter. Finally, Quantum Portfolio Management LLC bought a new stake in shares of BioNTech in the first quarter valued at about $203,000. Institutional investors own 15.52% of the company’s stock.

BioNTech Trading Up 0.8%

Shares of BioNTech stock opened at $97.64 on Friday. BioNTech has a 12-month low of $79.52 and a 12-month high of $124.00. The stock has a market cap of $24.69 billion, a P/E ratio of -12.47 and a beta of 1.25. The company has a quick ratio of 7.80, a current ratio of 7.85 and a debt-to-equity ratio of 0.01. The business’s 50 day moving average is $98.94 and its 200-day moving average is $95.06.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing the consensus estimate of ($2.40) by ($0.13). The company had revenue of $122.31 million during the quarter, compared to analyst estimates of $180.18 million. BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The company’s quarterly revenue was down 59.5% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.60) EPS. Equities research analysts predict that BioNTech will post -6.37 earnings per share for the current fiscal year.

About BioNTech

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing therapies and vaccines for cancer and other serious diseases. The company’s research platform includes messenger RNA (mRNA), individualized cancer vaccines, immune-modulating therapies, cell therapies, and protein-based therapeutics.

BioNTech is best known for developing the Comirnaty COVID-19 vaccine in collaboration with Pfizer. Comirnaty uses mRNA technology to help stimulate an immune response against COVID-19 and has been distributed in markets around the world.